We are live on ! Find out more
O

OrbiMed Portfolio holdings

AUM $5.05B
1-Year Est. Return 125.28%
This Fund
S&P 500
This Quarter Est. Return
+13%
1 Year Est. Return
+125.28%
3 Year Est. Return
+334.72%
5 Year Est. Return
+344.07%
10 Year Est. Return
+2,748.76%
AUM
$10.5B
AUM Growth
+$923M
Cap. Flow
+$224M
Cap. Flow %
2.14%
Top 10 Hldgs %
34.54%
Holding
153
New
17
Increased
27
Reduced
30
Closed
10

Top Buys

Rank Stock Value
1
CMTA
Clementia Pharmaceuticals Inc.
CMTA
+$170M
2
AET
Aetna Inc
AET
+$79.5M
3
UHS icon
Universal Health Services
UHS
+$75.3M
4
KALA icon
KALA BIO
KALA
+$52.2M
5
IMMU
Immunomedics Inc
IMMU
+$50.5M

Top Sells

Rank Stock Value
1
HUM icon
Humana
HUM
+$185M
2
EW icon
Edwards Lifesciences
EW
+$51.3M
3
ICPT
Intercept Pharmaceuticals, Inc.
ICPT
+$50.6M
4
INSM icon
Insmed
INSM
+$48M
5
GKOS icon
Glaukos
GKOS
+$34.4M

Sector Composition

Rank Sector Weight
1 Healthcare 91.18%
2 Financials 2.54%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
NUVA
101
DELISTED
NuVasive, Inc.
NUVA
$12.2M 0.12%
220,700
+155,100
+236% +$10.3M
ARGX icon
102
argenx
ARGX
$55.1B
$11.3M 0.11%
500,000
– –
AUPH icon
103
Aurinia Pharmaceuticals
AUPH
$1.92B
$11.3M 0.11%
1,797,400
– –
PRQR icon
104
ProQR Therapeutics
PRQR
$243M
$11.1M 0.11%
2,295,346
-10,100
-0.4% -$52.4K
HRTX icon
105
Heron Therapeutics
HRTX
$92.3M
$10.5M 0.1%
650,000
– –
VRNA
106
DELISTED
Verona Pharma
VRNA
$10.2M 0.1%
666,666
– –
BMY icon
107
CALL
Bristol-Myers Squibb
BMY
$130B
$9.56M 0.09%
+150,000
New +$8.76M
LAB icon
108
Standard BioTools
LAB
$325M
$8.8M 0.08%
1,746,100
– –
LUMO
109
DELISTED
Lumos Pharma, Inc. Common Stock
LUMO
$8.46M 0.08%
92,364
-112,747
-55% -$8.65M
DCPH
110
DELISTED
Deciphera Pharmaceuticals, Inc. Common Stock
DCPH
$7.49M 0.07%
+394,270
New +$7.22M
ALKS icon
111
Alkermes
ALKS
$8.08B
$7.37M 0.07%
145,000
– –
SYRE icon
112
Spyre Therapeutics
SYRE
$8.35B
$7.24M 0.07%
58,781
– –
TEVA icon
113
Teva Pharmaceuticals
TEVA
$39.7B
$7.14M 0.07%
405,500
-120,800
-23% -$2.72M
SRPT icon
114
CALL
Sarepta Therapeutics
SRPT
$1.65B
$6.8M 0.07%
+150,000
New +$5.99M
CRSP icon
115
CRISPR Therapeutics
CRSP
$4.63B
$6.65M 0.06%
372,191
– –
RDHL
116
Redhill Biopharma
RDHL
$4.26M
$6.11M 0.06%
565
– –
HALO icon
117
Halozyme
HALO
$9.86B
$6.08M 0.06%
350,000
– –
SRRA
118
DELISTED
Sierra Oncology, Inc. Common Stock
SRRA
$5.74M 0.05%
92,593
– –
ZBH icon
119
Zimmer Biomet
ZBH
$18.7B
$5.74M 0.05%
50,470
– –
SNDX icon
120
Syndax Pharmaceuticals
SNDX
$1.68B
$5.11M 0.05%
437,000
– –
CBIO
121
Crescent Biopharma
CBIO
$572M
$4.72M 0.05%
3,376
– –
MCRB icon
122
Seres Therapeutics
MCRB
$45.9M
$3.52M 0.03%
+10,973
New +$3M
MRNS
123
DELISTED
Marinus Pharmaceuticals, Inc
MRNS
$3.33M 0.03%
141,900
– –
INFI
124
DELISTED
Infinity Pharmaceuticals, Inc.
INFI
$2.94M 0.03%
2,207,245
-1,043,055
-32% -$1.3M
BHC icon
125
Bausch Health
BHC
$1.7B
$2.79M 0.03%
194,900
– –
2 3 4
5
6

Similar funds

HSA
HBK Sorce Advisory Erie, Pennsylvania $5.05B AUM 16.64% 1-Year Est. Return
NL
NEPC LLC Boston, Massachusetts $5.02B AUM 7.87% 1-Year Est. Return
BPWM
Badgley Phelps Wealth Managers Seattle, Washington $5.02B AUM 21.87% 1-Year Est. Return
LFG
Lazard Frères Gestion Paris, France $5.07B AUM 20.66% 1-Year Est. Return
JIM
Jensen Investment Management Lake Oswego, Oregon $5.07B AUM 4.98% 1-Year Est. Return
CTC
Central Trust Company Jefferson City, Missouri $5.08B AUM 25.65% 1-Year Est. Return
PAMP
Polar Asset Management Partners Toronto, Ontario, Canada $5.01B AUM 35.27% 1-Year Est. Return
SGM
Skye Global Management West Palm Beach, Florida $5B AUM 11.9% 1-Year Est. Return

OrbiMed's Q3 2017 Portfolio in Review

As of Q3 2017, OrbiMed held 153 positions worth $10.5B, up 9.7% from $9.54B the previous quarter. Its ten largest holdings account for 35% of the portfolio.

OrbiMed's Q3 2017 filing shows 17 new, 27 increased, 30 reduced and 10 closed positions. Its largest new stake was Clementia Pharmaceuticals Inc.: 10,425,225 shares worth $176M. The largest sale was Humana, an estimated $185M.

By sector, the portfolio is most concentrated in Healthcare at 91% of assets, down from 93% a quarter earlier, followed by Financials.

  • OrbiMed's largest Q3 2017 buy was Clementia Pharmaceuticals Inc.: 10,425,225 shares worth $176M.
  • OrbiMed added most to Aetna Inc in Q3 2017, an estimated $79.5M increase.
  • OrbiMed's biggest Q3 2017 reduction was Edwards Lifesciences, cutting an estimated $51.3M.
  • OrbiMed fully exited Humana in Q3 2017, selling an estimated $185M.
  • OrbiMed's ten largest holdings make up 35% of its $10.5B portfolio in Q3 2017.
  • OrbiMed opened 17 new positions and closed 10 in Q3 2017.
  • OrbiMed's portfolio value rose 9.7% quarter-over-quarter to $10.5B.

Based on OrbiMed's 13F filing for Q3 2017, filed 14 Nov 2017.